You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
The pace of innovation in biotechnology is accelerating at a rapid clip. It took researchers 13 years to sequence the first full human genome. By contrast, it only took CRISPR Therapeutics (NASDAQ: CRSP) 10 years to bring their "molecular scissors" concept to market. With machine learning and artificial intelligence in the mix, biotech innovation -- especially in the area of gene editing/therapy -- is highly likely to speed up even further in the years to come. That's an exciting proposition for investors.
Gene editing could unlock billions of dollars in latent value for shareholders, as pioneers in the space race to develop one-time functional cures for scores of inherited diseases. All that being said, there will be unexpected clinical, regulatory, and commercial setbacks, and predicting the future winners in this fledgling industry is essentially a fool's game at this nascent stage. Fortunately, you don't have to pick one or two gene editing stocks. Here is a far better approach with markedly higher odds of success over the long run.
Image Source: Getty Images.
Source Fool.com
